ALEXANDRIA, Va., June 19 -- United States Patent no. 12,329,825, issued on June 17, was assigned to Dyne Therapeutics Inc. (Waltham, Mass.).
"Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject" was invented by Romesh R. Subramanian (Framingham, Mass.), Mohammed T. Qatanani (Waltham, Mass.) and Timothy Weeden (Waltham, Mass.).
According to the abstract* released by the U.S. Patent & Trademark Office: "Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an inter...